Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;11(10):2916-2923.
doi: 10.1111/1759-7714.13631. Epub 2020 Aug 24.

Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review

Tao Zhang #  1 , Kunpeng Xu #  1 , Nan Bi  1 , Li Zhang  2 , Wei Jiang  3 , Jun Liang  3 , Lei Deng  1 , Xin Wang  1 , Jianyang Wang  1 , Jie Wang  4 , Luhua Wang  1   3
Affiliations
Review

Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review

Tao Zhang et al. Thorac Cancer. 2020 Oct.

Abstract

Background: The PACIFIC study has defined a new standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) in the form of immune checkpoint inhibitor (ICI) consolidation therapy. However, there is little specific data pertaining to the safety and efficacy of this approach in Chinese NSCLC patients.

Methods: This was a prospective multicenter cohort study. Between September 2018 and January 2020, patients with unresectable stage III NSCLC that had undergone chemoradiation therapy (CRT) and ICI consolidation treatment were enrolled in this study. The short-term safety, tolerability, and efficacy of ICI combination with CRT were evaluated in these patients.

Results: Of the 20 Chinese patients eligible for inclusion, 17 (85.0%) underwent concurrent CRT treatment. In these patients, a median period of 40.5 days (range: 1-85 days) passed between the end of CRT and initiation of consolidation therapy. Pneumonitis occurred in 80.0% of patients, with seven (35.0%) being diagnosed with grade 1 pneumonitis and nine (45.0%) with grade 2 pneumonitis. No patients experienced grade 3 or higher pneumonitis or other ICI-related toxicities. Lung V20 ≥ 20% was associated with higher grade 2 pneumonitis (77.8%; ≥20% vs. 18.2%; <20%, P = 0.027). The overall response rate (ORR) in these patients was 95.0%. Over a median follow-up period of 11.3 months (range: 6.2-21.8 months), 12-month PFS of these patients were 89.5% (95% CI: 76.7-100.0%), and 12 months OS was 100.0%.

Conclusions: These data indicate that ICI consolidation therapy can achieve favorable short-term efficacy, while exhibiting good safety and acceptable toxicity profiles in Chinese patients with unresectable stage III NSCLC.

Key points: Significant findings of the study This is the first report evaluating the safety and efficacy of ICI consolidation therapy after chemoradiotherapy in China. Our results indicate that ICI consolidation is associated with favorable efficacy and no severe pneumonitis incidence in Chinese patients undergoing both anti-PD-1 and anti-PD-L1 monoclonal antibody consolidation. What this study adds Post-hoc analysis of the Japanese subgroup in the PACIFIC study suggested that consolidation therapy may be associated with increased pneumonitis incidence in Asian patients. However, our findings indicate that consolidation therapy is safe and tolerable in Chinese patients with unresectable stage III NSCLC.

Keywords: Chinese; PD-1; PD-L1; pneumonitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The relationship between dose parameters (V20) and radiation pneumonitis.
Figure 2
Figure 2
The best responses of patients for ICI consolidation after CRT. The dashed line corresponds to a 30% reduction in target lesion size as defined by the RECIST 1.1 criteria. formula image, CR; formula image, PR; formula image, SD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70 (1): 7–30. - PubMed
    1. Yang P, Allen MS, Aubry MC et al Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128 (1): 452–62. - PubMed
    1. Govindan R, Bogart J, Vokes EE. Locally advanced non‐small cell lung cancer: The past, present, and future. J Thorac Oncol 2008; 3 (8): 917–28. - PubMed
    1. Yamamoto N, Nakagawa K, Nishimura Y et al Phase III study comparing second‐ and third‐generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non‐small‐cell lung cancer: West Japan thoracic oncology group WJTOG0105. J Clin Oncol 2010; 28 (23): 3739–45. - PubMed
    1. Furuse K, Fukuoka M, Kawahara M et al Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non‐small‐cell lung cancer. J Clin Oncol 1999; 17 (9): 2692–9. - PubMed

Substances